الفهرس 
acknowledgementOnly 14 pages are availabe for public view
 |  | from | 106 |  |  |
| | | from | 106 | | |
Abstract
Umbilical cord blood (UCB) is an alternative source of hematopoietic stem cells for transplantation in the treatment of hematological malignancies, marrow failure, immunodeficiencies, hemoglobinopathies and inherited metabolic diseases. It has greatly contributed to increase the feasibility to transplantation for many patients in need.
CD34+ cells are multipotent stem cells that give rise to all cell types in blood. These stem cells are typically found in the bone marrow; less than 1% of nucleated cells in the blood are CD34.Approximately 1% of the mononuclear cord blood cells express the CD34 antigen, which represents the cardinal marker for (HSCs).
The biggest advantages of UCB cells are the non-invasive nature of collection and their easy characterization and banking.
The main drawback of UCB is the limited number of cells available from a single unit. This translates clinically into a higher incidence of engraftment failure. However ex vivo expansion of UCB stem cells have a greater probability of success, at the moment, improvements in the methods of collecting and selecting CBU are the directions being taken to increase the efficacy and reduce the costs of cord blood banking and transplantation.
Banking cord blood is a way of preserving potentially life-saving cells that usually get thrown away after birth.
The present study evaluated the recovery rate of CD34 & MNC after processing cord blood units using AXP & SEPAX systems. Also, in our study, we compare processing three groups of initial cord blood volume ( <100 ml , 100-150 ml & >150 ml ) between AXP & SEPAX systems to detect if the initial cord volume affect the recovery rate of MNC & CD34 and if one of the two systems is better than the other in separation of any of the 3 groups.
The results of the current study revealed that MNC recovery was nearly the same for both systems AXP & SEPAX but the AXP system is better than the SEPAX system in the recovery rate of CD34. Also, we found that the initial cord blood volume has no effect on the recovery rate of MNC & CD34 after processing either by AXP system or SEPAX system and there is no difference between the two systems in separation of any of the 3 initial volume groups.